Endozepine stupor: Disease or deception? A critical review

Sleep

Volumn 27, Issue 8, 2004, Pages 1597-1599

  Granot, Ron ^a,d   Berkovic, Samuel F ^b   Patterson, Scott ^d   Hopwood, Malcolm ^b   Drummer, Olaf H ^c   Mackenzie, Rod ^d  

^a PRINCE OF WALES HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Vic Institute of Forensic Medicine   (Australia)

^d NONE

Author keywords

Benzodiazepine; Coma; Endozepine; Idiopathic stupor; Munchausen syndrome by proxy; Recurrent stupor

Indexed keywords

BENZODIAZEPINE; BROMAZEPAM; DIAZEPAM BINDING INHIBITOR; ENDOZEPINE 4; LORAZEPAM; TRIAZOLAM; UNCLASSIFIED DRUG; ZALEPLON; ZOLPIDEM; ZOPICLONE;

CLINICAL FEATURE; COMA; DRUG INTOXICATION; ELECTROENCEPHALOGRAM; ENDOZEPINE STUPOR; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IDIOPATHIC DISEASE; MASS SPECTROMETRY; MUNCHAUSEN SYNDROME; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; STUPOR; SYNDROME;

EID: 11144267822     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: 10.1093/sleep/27.8.1597     Document Type: Review

References (40)

1. rd ed. Philadelphia: FA Davis; 1980.
2. Rothstein JD, Guidotti A, Costa E. Release of endogenous benzodiazepine receptor ligands (endozepines) from cultured neurons. Neurosci Lett 1992;143:210-14.
3. Tinuper P, Montagna P, Cortelli P, et al. Idiopathic recurring stupor: a case with possible involvement of the gamma-aminobutyric acid (GABA)ergic system. Ann Neurol 1992;315:503-6.
4. Tinuper P, Montagna P, Plazzi G, et al. Idiopathic recurring stupor. Neurology 1994;444:621-5.
5. Lugaresi E, Montagna P, Tinuper P, et al. Endozepine stupor. Recurring stupor linked to endozepine-4 accumulation. Brain 1998;121:127-33.
6. Rothstein JD, Garland W, Puia G, Guidotti A, Weber RJ, Costa E. Purification and characterization of naturally occurring benzodiazepine receptor ligands in rat and human brain. J Neurochem 1992;586:2102-15.
7. Rothstein JD, Guidotti A, Tinuper P, et al. Endogenous benzodiazepine receptor ligands in ldiopathic recurring stupor. Lancet 1992;340:1002-4.
8. Tinuper P, Montagna P, Plazzi G, Lugaresi E. Transient unresponsiveness in the elderly: possible episodes of idiopathic recurring stupor. Arch Neurol 1995;523:232.
9. Soriani S, Carrozzi M, De Carlo L et al. Endozepine stupor in children. Cephalalgia 1997;176:658-61.
10. Lotz BP, Schutte CM, Bartel PR, Jacobs E. Recurrent attacks of unconsciousness with diffuse EEG alpha activity. Sleep 1993;167:671-7.
11. Shimoe Y, Fukutake T, Nakai R, Hirayama K. Recurring consciousness disturbance with elevation of endogenous benzodiazepine-like activity. Rinsho Shinkeigaku 1996;363:495-8.
12. Lugaresi E, Montagna P, Tinuper P, Plazzi G, Gallassi R. Suspected covert lorazepam administration misdiagnosed as recurrent endozepine stupor. Brain 1998;121:2201.
13. Huberfeld G, Dupont S, Hazemann P, Adam C, Baulac M, Pierrot-Deseilligny C. Recurrent idiopathic stupor in a patient: responsibility of exogenous or endogenous benzodiazepines? Rev Neurol 2002;158:824-6.
14. Granot R, Berkovic SF, Patterson S, Hopwood M, Mackenzie R. Idiopathic recurrent stupor: a warning. J Neurol Neurosurg Psychiatry 2004;753:368-9.
15. Drummer OH. Methods for the measurement of benzodiazepines in biological samples. J Chromatogr B Biomed Sci Appl 1998 7131:201-25.
16. Maurer HH, Kraemer T, Kratzsch C, Peters FT, Weber AA. Negative ion chemical ionization gas chromatography-mass spectrometry and atmospheric pressure chemical ionization liquid chromatography-mass spectrometry of low-dosed and/or polar drugs in plasma. Ther Drug Monit 2002;241:117-24.
17. Ball JA, Ghatei MA, Sekiya K, Krausz T, Bloom SR. Diazepam binding inhibitor-like immunoreactivity(51-70): distribution in human brain, spinal cord and peripheral tissues. Brain Res 1989;4792:300-5.
18. Ferrero P, Santi MR, Conti-Tronconi B, Costa E, Guidotti A. Study of an octadecaneuropeptide derived from diazepam binding inhibitor (DBI): biological activity and presence in rat brain. Proc Natl Acad Sci U S A 1986;833:827-31.
19. Slobodyansky E, Guidotti A, Wambebe C, Berkovich A, Costa E. Isolation and characterization of a rat brain triakontatetraneuropeptide, a posttranslational product of diazepam binding inhibitor: specific action at the Ro 5-4864 recognition site. J Neurochem 1989;534:1276-84.
20. Berkovich A, McPhie P, Campagnone M, Guidotti A, Hensley P. A natural processing product of rat diazepam binding inhibitor, triakontatetraneuropeptide (diazepam binding inhibitor 17-50) contains an alpha-helix, which allows discrimination between benzodiazepine binding site subtypes. Mol Pharmacol 1990;372:164-72.
21. Patte C, Gandolfo P, Leprince J et al. GABA inhibits endozepine release from cultured rat astrocytes. Glia 1999;254:404-11.
22. Alho H, Harjuntausta T, Schultz R, Pelto-Huikko M, Bovolin P. Immunohistochemistry of diazepam binding inhibitor (DBI) in the central nervous system and peripheral organs: its possible role as an endogenous regulator of different types of benzodiazepine receptors. Neuropharmacology 1991;30:1381-6.
23. Hall PF. The role of endozepine in the regulation of steroid synthesis. Mol Neurobiol 1995;101:1-17.
24. Gandolfo P, Patte C, Leprince J, Thoumas JL, Vaudry H, Tonon MC. The stimulatory effect of the octadecaneuropeptide (ODN) on cytosolic Ca2+ in rat astrocytes is not mediated through classical benzodiazepine receptors. Eur J Pharmacol 1997;322:275-81.
25. Mateos-Verchere JG, Leprince J, Tonon MC, Vaudry H, Costentin J. The octadecaneuropeptide ODN induces anxiety in rodents: possible involvement of a shorter biologically active fragment. Peptides 1998;195:841-8.
26. Ferrero P, Guidotti A, Conti-Tronconi B, Costa E. A brain octadecaneuropeptide generated by tryptic digestion of DBI (diazepam binding inhibitor) functions as a proconflict ligand of benzodiazepine recognition sites. Neuropharmacology 1984;2311:1359-62.
27. Zhdanova IV, Kordzadze RN, Pliashkevich I. Changes in the emotionally conditioned behavior of rats under the influence of the hexapeptide fragment GLLDLK of the protein inhibitor of diazepam binding. Biulleten Eksperimentalnoi Biologii i Meditsiny 1991;1112:165-8.
28. Parrott RF, Vellucci SV, Goode JA. Behavioral and hormonal effects of centrally injected "anxiogenic" neuropeptides in growing pigs. Pharmacology, Biochemistry & Behavior 2000;651:123-9.
29. Guidotti A, Forchetti CM, Corda MG, Konkel D, Bennett CD, Costa E. Isolation, characterization, and purification to homogeneity of an endogenous polypeptide with agonistic action on benzodiazepine receptors. Proc Natl Acad Sci U S A 1983;8011:3531-5.
30. Compere V, Li S, Leprince J, Tonon MC, Vaudry H, Pelletier G Effect of intracerebroventricular administration of the octadecaneuropeptide on the expression of pro-opiomelanocortin, neuropeptide Y and corticotropin-releasing hormone mRNAs in rat hypothalamus. J Neuroendocrinol 2003;152:197-203.
31. Dong E, Matsumoto K, Tohda M, Watanabe H. Involvement of diazepam binding inhibitor and its fragment octadecaneuropeptide in social isolation stress-induced decrease in pentobarbital sleep in mice. Life Sci 1999;6419:1779-84.
32. Rosenberg DA. Web of deceit: a literature review of Munchausen syndrome by proxy. Child Abuse Neglect 1987;114:547-63.
33. Bools C. Factitious illness by proxy. Munchausen syndrome by proxy. Br J Psychiatry 1996;1693:268-75.
34. Meadow R. Munchausen syndrome by proxy. The hinterland of child abuse. Lancet 1977;2:343.
35. Owen L, Ellis M, Shield J. Deliberate sulphonylurea poisoning mimicking hyperinsulinemia of infancy. Arch Dis Child 2000;825:392-3.
36. Sigal MD, Altmark D, Carmel I. Munchausen syndrome by adult proxy: a perpetrator abusing two adults. J Nerv Ment Dis 1986:17411:696-8.
37. Krebs MO, Bouden A, Loo H, Olie JP. Munchhausen syndrome by proxy between two adults. Presse Med 1996;2512:583-6.
38. Kaufman-Walther V, Laederach-Hofmann K. Munchausen syndrome in a 66-year-old patient. Schweiz Rundsch Med Prax 1997;620:850-5.
39. Ben Chetrit E, Melmed RN. Recurrent hypoglycaemia in multiple myeloma: a case of Munchausen syndrome by proxy in an elderly patient. J Intern Med 1998;2442:175-8.
40. Somani VK. Witchcraft's syndrome: Munchausen's syndrome by proxy. Int J Dermatol 1998;373:229-30.